Acelyrin (NASDAQ:SLRN - Get Free Report) will be issuing its quarterly earnings data after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Acelyrin (NASDAQ:SLRN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.08). During the same quarter in the prior year, the business earned ($0.56) earnings per share. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Acelyrin Stock Performance
Shares of SLRN traded down $0.05 during trading hours on Thursday, hitting $5.95. The stock had a trading volume of 380,841 shares, compared to its average volume of 1,040,242. The firm has a market capitalization of $593.87 million, a price-to-earnings ratio of -2.11 and a beta of 1.98. The firm has a 50-day moving average price of $5.26 and a 200 day moving average price of $4.96. Acelyrin has a fifty-two week low of $3.36 and a fifty-two week high of $9.25.
Analysts Set New Price Targets
Several brokerages have commented on SLRN. HC Wainwright lowered Acelyrin from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $18.00 to $6.00 in a report on Wednesday, August 14th. Piper Sandler cut their price target on shares of Acelyrin from $68.00 to $20.00 and set an "overweight" rating for the company in a report on Wednesday, August 14th. Morgan Stanley decreased their price objective on shares of Acelyrin from $13.00 to $6.00 and set an "equal weight" rating on the stock in a report on Monday, August 19th. Finally, Wells Fargo & Company upped their price target on shares of Acelyrin from $13.00 to $15.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 16th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Acelyrin has a consensus rating of "Moderate Buy" and an average target price of $11.17.
Read Our Latest Stock Analysis on Acelyrin
Acelyrin Company Profile
(
Get Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Further Reading
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
